| Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL J Gauthier, N Gazeau, AV Hirayama, JA Hill, V Wu, A Cearley, P Perkins, ... Blood, The Journal of the American Society of Hematology 139 (26), 3722-3731, 2022 | 44 | 2022 |
| Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy N Gazeau, EC Liang, JM Voutsinas, P Barba, G Iacoboni, M Kwon, ... Transplantation and Cellular Therapy 29 (7), 430-437, 2023 | 36* | 2023 |
| Effective anti-BCMA retreatment in multiple myeloma N Gazeau, D Beauvais, I Yakoub-Agha, S Mitra, TB Campbell, T Facon, ... Blood Advances 5 (15), 3016-3020, 2021 | 32 | 2021 |
| Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma AV Hirayama, EL Kimble, JH Wright, S Fiorenza, J Gauthier, JM Voutsinas, ... Blood Advances 8 (2), 453-467, 2024 | 2 | 2024 |
| Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes G Escure, E Fournier, C Saade, LHB Issa, I Arib, R Tilmont, N Gazeau, ... Haematologica 109 (4), 1289, 2024 | 1 | 2024 |
| Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma N Gazeau, S Mitra, M Nudel, R Tilmont, P Chauvet, M Srour, AS Moreau, ... British journal of haematology 202 (2), 434-436, 2023 | 1 | 2023 |
| Efficacy and safety of CAR T-cell therapy using a fully human CD19-targeted binder in adults with relapsed/refractory B-ALL J Gauthier, N Gazeau, S Fiorenza, EL Kimble, A Vinaud Hirayama, ... Blood 140 (Supplement 1), 10360-10362, 2022 | 1* | 2022 |
| Genomic profiling of Mycosis Fungoides identifies patients at high risk of disease progression L Fléchon, I Arib, AK Dutta, L Hasan Bou Issa, R Sklavenitis-Pistofidis, ... Blood Advances, bloodadvances. 2023012125, 2024 | | 2024 |
| Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia N Gazeau, C Derrieux, O Nibourel, C Berthon, N Grardel, L Goursaud, ... Leukemia 34 (8), 2230-2233, 2020 | | 2020 |
| Le microenvironnement immun et les immunothérapies dans le myélome multiple. N Gazeau, S Manier Hématologie, 2020 | | 2020 |
Jordan GauthierFred Hutchinson Cancer Research CenterVerified email at fredhutch.org
